18F-FDG PET/CT in the initial assessment and for follow-up in patients with tuberculosis

Clinical Nuclear Medicine

Volumn 41, Issue 4, 2016, Pages e187-e194

  Stelzmueller, Ingrid ^a   Huber, Helmut ^a   Wunn, Rainer ^b   Hodolic, Marina ^c   Mandl, Michael ^a   Lamprecht, Bernd ^a   Schinko, Herwig ^a   Fellner, Franz ^b   Skanjeti, Andrea ^a   Giammarile, Francesco ^a   Colletti, Patrick M ^d   Rubello, Domenico ^e   Gabriel, Michael ^f  

^a Department of Pneumology ^*  (France)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

^c IASON GmbH   (Austria)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CT; FDG PET; Treatment response; Tuberculosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUBERCULOSTATIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MALE; MINIMAL RESIDUAL DISEASE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIDRUG RESISTANT TUBERCULOSIS; PET-CT SCANNER; REMISSION; RETROSPECTIVE STUDY; DIAGNOSTIC IMAGING; EVALUATION STUDY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; TUBERCULOSIS; X-RAY COMPUTED TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS;

EID: 84951335803     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001102     Document Type: Article

References (22)

1. World Health Organization. Treatment of tuberculosis guidelines, Fourth Edition. Available at: http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833- eng.pdf?ua=1&ua=1. Accessed October 11, 2015.
2. Guirado E, Schlesinger LS. Modeling the Mycobacterium tuberculosis granuloma-the critical battlefield in host immunity and disease. Front Immunol. 2013;4:98.
3. Flick H, Rumetshofer R, Wurzinger G. Tuberkulose. Wien Klin Wochenschr Educ. 2012;37:234-241.
4. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician. 2005;72:1761-1768.
5. Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis. 2015; 32:87-93.
6. Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104-112.
7. 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med. 2009;23:427-435.
8. 18F-FDG-PET/CT scanning in patients with granulomatous lung disease. Nucl Med Commun. 2015;36:430-437.
9. 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53:1543-1549.
10. Kim DW, Park SA, Kim CG. Dual-time-point positron emission tomography findings of benign mediastinal fluorine-18-fluorodeoxyglucose uptake in tuberculosis-endemic region. Indian J Nucl Med. 2011;26:3-6.
11. Tian G, Xiao Y, Chen B, et al. FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis. Acta Radiol. 2010;51: 1002-1006.
12. Sathekge M, Maes A, Kgomo M, et al. Impact of FDG PET on the management of TBC treatment. A pilot study. Nuklearmedizin. 2010;49:35-40.
13. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35:1537-1543.
14. Glaudemans AW, de Vries EF, Galli F, et al. The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036.
15. Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. Semin Nucl Med. 2013;43:349-366.
16. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis. 2012;16:1180-1185.
17. 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging. 2009;36:632-639.
18. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(Suppl 1):122S-150S.
19. 18F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol. 2015;3:1-8.
20. 18FDG-PET for monitoring disease activity in an HIV-1 positive patient with disseminated chronic osteomyelitic brucellosis due to Brucella melitensis. Eur J Nucl Med Mol Imaging. 2005; 32:630.
21. 18F-FDG PET and PET/CT. Curr Opin Pulm Med. 2014;20: 287-293.
22. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with tuberculosis. Jpn J Radiol. 2013;31:511-520.